Home Blog Page 444

WePlay’s Southeast Asia Lunar New Year Campaign Featured in App Store Today and Today Collection

SINGAPORE, March 24, 2026 /PRNewswire/ — Global social entertainment platform WePlay operated by WEJOY PTE. LTD., recently received strong recognition from App Store Today for its Lunar New Year campaign launched across Southeast Asia in February. The themed event was not only selected for the App Store Today Lunar New Year feature, but was also included in the broader App Store Today Collection, making it one of the most highlighted social entertainment experiences during the festive season in the region.

WePlay’s Southeast Asia Lunar New Year Campaign Featured in App Store Today and Today Collection
WePlay’s Southeast Asia Lunar New Year Campaign Featured in App Store Today and Today Collection

Dual Recognition from App Store Today

App Store Today is one of the most influential editorial content sections within the Apple ecosystem, known for its curated selections and high editorial standards. Being featured both in the Today thematic section and the Today Collection indicates that WePlay’s campaign stood out not only in terms of product design and interactive experience, but also in its creative approach to festive storytelling and localized content operations.

Looking ahead, WePlay plans to continue developing culturally relevant themed events tailored to different regional markets. By combining gaming, voice interaction, and community-driven content, the platform aims to build a global social entertainment ecosystem where “games serve as the medium, social interaction as the core, and content as the driving force,” delivering memorable experiences for young users worldwide.

About WePlay

WePlay is a global social entertainment platform operated by WEJOY PTE. LTD., headquartered in Singapore. With the mission to “Bring joy and friends to young people around the world,” WePlay is dedicated to connecting global youth through voice communication and interactive entertainment. The platform combines gaming, voice rooms, party interaction features, and more, providing users with low-barrier, highly interactive social experiences.

About WEJOY PTE. LTD.

WEJOY PTE. LTD. is an internet company based in Singapore, founded on October 23, 2020. As a company with a global vision and innovative spirit, we are dedicated to expanding in the social and gaming business sectors worldwide. We focus on the development and operation of social board games and casual games, with a particular emphasis on creating innovative and engaging gaming experiences that connect people around the world. Currently, we are actively expanding into international markets, and in the future, we aim to make a significant impact on the global stage.

Media Contact

Company: WEJOY PTE. LTD.
Contact: Bryant
Email: bryant@wejoysg.com 

WePlay Website: https://weplayapp.com/
WeJoy Website: https://wejoyhub.com/

SMARTIES™ Awards 2026 Call for Entries, Celebrating Marketing That Drives Real Business Impact

SINGAPORE, March 24, 2026 /PRNewswire/ — The Marketing + Media Alliance (MMA) proudly announces the opening of entries for the 2026 SMARTIES™ Awards, the premier marketing awards program that honors trailblazing brands, agencies, and marketers driving innovation and business impact.

SMARTIES™ celebrate marketing that drives growth, strengthens brand connections, and pushes the boundaries of innovation across the global marketing ecosystem.

SMARTIES™ Awards 2026 Call for Entries, Celebrating Marketing That Drives Real Business Impact
SMARTIES™ Awards 2026 Call for Entries, Celebrating Marketing That Drives Real Business Impact

As marketing continues to evolve through the integration of technology, creativity, data, and media, the SMARTIES™ framework has been updated for 2026 to better reflect how today marketing organizations operate and how impactful work is delivered today.

Continuing its mission to recognize marketing that drives growth, inspires innovation, and shapes the future of the industry, SMARTIES™ 2026 ensures the full spectrum of advance marketing excellence is celebrated. Critically, the same channels and categories will be available across all SMARTIES™ programs globally positioning the awards as a unified benchmark for marketing excellence while allowing regions to highlight the work that best represents their markets.

SMARTIES™ 2026 Channels
The program is organized into four key channels representing the pillars of marketing excellence today:

Purpose Driven Marketing
Campaigns that leverage the power of brands to drive meaningful societal and cultural impact, advancing causes such as sustainability, diversity, and inclusion.

Impact Marketing
Campaigns that deliver measurable business outcomes by strengthening brand relationships, enhancing customer experiences, and driving growth.

Media & Growth
Excellence in media strategy and execution, demonstrating how integrated media ecosystems effectively reach, engage, and grow audiences.

Creative & Innovation Impact
Breakthrough marketing powered by creativity, data, and emerging technologies to create new forms of brand engagement.

“Asia Pacific continues to be one of the most dynamic and innovative marketing regions in the world. The diversity of this region – its cultures, consumers, and digital ecosystems – means marketers here are constantly pioneering new approaches to drive genuine business impact. SMARTIES™ Asia Pacific exists to surface that innovation, benchmark it against the best in the world, and turn it into the learning that elevates the entire industry. The work coming out of this region deserves that platform,” says Rohit Dadwal, CEO of MMA APAC & Global Head of SMARTIES™ Worldwide.

Beyond the Trophy: Industry Recognition & Global Rankings
Winning a SMARTIES™ Award provides more than prestige. Awarded campaigns will be featured in MMA SMARTIES Business Impact Index, RECMA, and the WARC Media 100 Ranking, reinforcing their influence and credibility across the industry.

Showcase Your Marketing Excellence
Submit to SMARTIES™ 2026 Today!

Key Details for 2026 SMARTIES™ Entries

  • On time Deadline: Jul 9, 2026
  • Awards & Honors: Gold, Silver, and Bronze winners in each category; top honors include Best in Show, Juror’s Choice Award of the Year, Most Resilient Brand of the Year, Advertiser of the Year, Brand of the Year, Publisher of the Year, Enabling Technology Company of the Year, Media Agency of the Year, Creative Agency of the Year, Independent Agency of the Year, Holding Agency Company of the Year, Agency Network of the Year (Regional /Global award) and Specialist Agency of the Year
  • Judging Panel: Senior brand marketers and industry leaders will evaluate campaigns based on innovation, creativity, and measurable impact.
  • Entry Levels:

Marketers, agencies, and brands are encouraged to submit their best work and gain industry-wide recognition.

About the Marketing + Media Alliance (MMA)
The Marketing + Media Alliance (MMA) is the global, non-profit community of Chief Marketing Officers and senior marketing leaders advancing marketers’ ability to create value. Led by CMOs and supported by the entire ecosystem at the governance level — including brands, media, agencies, consultancies, AdTech, and MarTech — MMA develops evidence-based models, frameworks, and tools validated through multi-year, multi-million-dollar Think Tanks and Labs.

Headquartered in New York City, with operations in 16 countries across APAC, Europe, MEA, LATAM, and North America, MMA has more than 825 corporate members who gather at 62+ MMA conferences worldwide, and flagship gatherings in the APAC, including MMA Innovate, CEO&CMO Summit, MMA Executive Dialogues, SMARTIES Unplugged, MMA IMPACT and MMA SMARTIES. Learn more at https://mmaglobal.com/

The Marketing + Media includes the world’s most influential marketers and partners, including Unilever, P&G, Grab, McDonalds, Coca Cola, Google, TikTok, Facebook, Diageo, Mondelez, Heineken, Pepsi, Perfetti, Affle, Emtek Group Indonesia, GoTo Gojek Tokopedia, Mayora, Godrej, Reliance – and many more.

About SMARTIES™
SMARTIES™ is the prestigious marketing awards program hosted by MMA, recognizing excellence in marketing effectiveness and innovation. The SMARTIES Awards celebrate campaigns that push creative boundaries while delivering measurable business impact. With programs spanning local, regional, and global markets, SMARTIES has become the industry’s most respected benchmark for marketing that drives real growth.

PlasmaLeap Funding Shows Appetite for Safeguarding Fertiliser Supply

Industry-aligned local strategic investors including GRDC, Hort Innovation, GrainCorp and Agnition Ventures all joined recent Series A round

  • Australian farmers face soaring fertiliser prices as events such as Middle East conflict curtail supply
  • PlasmaLeap technology reduces exposure to price shocks and supply disruptions, while lowering emissions

SYDNEY, March 24, 2026 /PRNewswire/ — PlasmaLeap Technologies, the Australian company pioneering zero-emissions production of ammonia and nitric acid, said its recent A$30 million ($21 million) fundraising shows strong support from leading Australian agribusinesses and industry organisations for technology that can safeguard fertiliser supply.

The Series A round attracted investment from Grains Research and Development Corporation (GRDC), Hort Innovation, and GrainCorp through funds managed in partnership with Artesian, as well as New Zealand’s Agnition Ventures (Corporate VC of Ravensdown Co-operative). Gates Foundation, Investible, Yara Growth Ventures (The VC unit of Yara International), UniSuper and Twynam also participated.

PlasmaLeap, which was spun out of the University of Sydney, has developed a patented reactor that can produce ammonia and nitrate – key ingredients in fertiliser – using only air, water and renewable electricity. Fertiliser prices have leapt following the start of the war in the Middle East, which supplies 45% of the world’s traded nitrogen fertilizer, with approximately one third of globally traded fertilisers passing through the Strait of Hormuz.

“The conflict in the Gulf has highlighted the risks to nitrogen fertiliser supply and the very real risks to farmers – and consumers – from price shocks,” PlasmaLeap CEO and co-founder Frere Byrne said. “Anecdotally, we’re hearing that lack of diesel is affecting planting decisions, while local fertiliser supplies are quickly being exhausted. Our technology removes some of that risk by enabling farmers to produce fertiliser themselves, which has crucial benefits in terms of derisking supply chains, and reducing emissions.”

GRDC Managing Director Nigel Hart said technologies that improve fertiliser supply resilience and reduce emissions were strategically important for the Australian grains sector.

“PlasmaLeap’s approach to decentralised nitrogen production has the potential to strengthen supply chains while supporting more sustainable farming systems. GRDC is pleased to support the continued development and evaluation of this technology for Australian growers,” Mr Hart said.

GrainCorp Strategy and Ventures Manager Zack Atlas said: “At GrainCorp Ventures, we’re committed to investing in innovative technologies that deliver value for growers while improving the sustainability and resilience of agricultural supply chains. PlasmaLeap’s clean, decentralised fertiliser technology has the potential to help growers of all sizes lower emissions, reduce costs, and drive meaningful decarbonisation efforts.”

Anthony Kachenko, General Manager – Production & Sustainability R&D at Hort Innovation, said the investment reflects the role of innovation in strengthening grower resilience and sustainability.

“Access to reliable, affordable fertiliser is critical for horticulture growers, particularly as input costs and supply chain pressures continue to rise,” Kachenko said. “Technologies like PlasmaLeap’s, which enable on‑farm and localised production using renewable energy, have the potential to improve supply security while also reducing emissions – supporting both productivity and long‑term sustainability outcomes for Australian growers.”

This round demonstrates cross-sectorial backing for world-leading technology tackling pressing national agriculture needs, and evidences a growing pool of local industry-aligned capital with tailored-strategic mandates suitable to fund industry growth and transformation.

Proceeds from the raising will be used to progress first-of-a-kind fertiliser hubs in NSW and Tasmania, expand field trials and further develop PlasmaLeap’s core technology. Longer term opportunities for the technology beyond fertiliser include sustainable fuels and energy systems.

About PlasmaLeap:

PlasmaLeap designs, manufactures, and distributes the world’s most advanced zero-emissions modular chemical reactors for hard-to-abate industries including agriculture, energy, and transport. Our mission is to build accessible, sustainable technology for global fuel and chemical production. Headquartered in Sydney, PlasmaLeap’s state-of-the-art chemical plants are disrupting the chemical sector, using only air, water and electricity to create valuable fuels, fertilisers, and industrial chemicals with marked-leading energy performance and production rates. PlasmaLeap is a grant recipient of The Gates Foundation, the 2025 winner of SVG Thrive, a finalist in Petronas Future Tech 4.0, and a 2024 Australian nominee for the Earthshot prize.

Interior Design Trends Singapore Homeowners Are Embracing in 2026

SINGAPORE, March 24, 2026 /PRNewswire/ — As Singapore homeowners continue to invest in improving their living spaces, interior design trends are evolving to reflect changing lifestyles, practical needs, and aesthetic preferences. From space-saving solutions to personalised design concepts, homeowners today are prioritising both functionality and comfort when renovating their homes.

Industry professionals note that renovation projects in Singapore are increasingly influenced by lifestyle shifts, remote work arrangements, and the desire for homes that provide both relaxation and productivity.

Interior design firms such as The Alchemists Design, a Singapore-based interior design and renovation company, have observed several emerging trends shaping residential interiors in the coming year.

1. Space-Optimised Layouts for HDB Living

With many Singaporeans living in HDB flats, space optimisation remains one of the most important aspects of interior design. Homeowners are increasingly focusing on layouts that maximise functionality without compromising aesthetics.

Open-concept layouts, built-in storage solutions and multi-functional furniture are becoming popular choices for homeowners looking to make the most of limited space. Thoughtful carpentry designs and custom storage features allow homeowners to maintain a clean and organised environment while improving everyday convenience.

2. Minimalist and Clutter-Free Interiors

Minimalism continues to influence interior design trends in Singapore. Clean lines, neutral colour palettes and simple furniture arrangements are increasingly preferred by homeowners who want calm and uncluttered living spaces.

This design approach not only enhances visual appeal but also improves functionality by reducing unnecessary items and creating a more spacious atmosphere.

Interior designers have also observed growing interest in Scandinavian-inspired interiors, which emphasise simplicity, natural lighting and practical design elements.

3. Personalised Design Concepts

Rather than relying solely on standard renovation packages, many homeowners are now seeking personalised interior design solutions that reflect their lifestyle and personality.

Custom carpentry, tailored storage systems and unique design themes allow homeowners to create spaces that better suit their daily routines.

According to interior design professionals, personalised design planning can also help address specific needs such as work-from-home setups, family-friendly layouts and improved storage capacity.

4. Durable and Sustainable Materials

Material selection has become an important consideration for homeowners who want their renovation investment to last over time. Durable materials that are easy to maintain are increasingly preferred, especially for frequently used spaces such as kitchens and living areas.

Sustainability is also becoming a factor in design decisions. Homeowners are exploring environmentally friendly materials, energy-efficient lighting and wood products that meet lower formaldehyde emission standards.

These choices not only contribute to healthier living environments but also improve long-term durability.

5. Practical Storage Solutions

Storage planning remains one of the most common concerns among homeowners renovating HDB flats. Designers are increasingly incorporating hidden storage, vertical shelving and built-in cabinetry to maximise available space.

Practical storage planning helps homeowners maintain tidy interiors while ensuring that everyday items remain easily accessible.

Interior design firms emphasise that effective storage solutions should be planned early during the design phase rather than added as an afterthought.

Balancing Design Aesthetics with Everyday Living

While design inspiration often comes from social media platforms such as Instagram and TikTok, professionals advise homeowners to balance aesthetic preferences with practical considerations.

A visually appealing home should also support everyday activities, whether it involves family living, entertaining guests or working from home.

Singapore-based interior design firm The Alchemists Design highlights that successful renovation projects often combine creative design concepts with practical planning to ensure that spaces remain functional and comfortable over time.

The firm undertakes both residential and commercial interior design projects, including HDB flats, condominiums, landed properties and commercial spaces, helping clients transform their ideas into well-designed environments.

In addition, the company offers HDB BTO and resale renovation packages for homeowners seeking practical, no-frills renovation solutions, alongside fully customised design services.

Creating Spaces That Reflect Modern Lifestyles

As Singapore’s built environment continues to evolve, interior design trends are increasingly shaped by the needs of modern homeowners and businesses.

From efficient space planning to personalised layouts and durable materials, these trends reflect a growing emphasis on creating spaces that support both lifestyle needs and long-term functionality.

With thoughtful planning and the guidance of experienced interior design professionals, property owners can create environments that are not only visually appealing but also practical for everyday use.

About The Alchemists Design

The Alchemists Design is a Singapore-based interior design and renovation company specialising in both residential and commercial projects, including HDB flats, condominiums, landed homes and commercial spaces.

The firm provides a range of services from customised interior design solutions to practical renovation packages for HDB BTO and resale flats. With a focus on functional design, quality workmanship and attentive customer service, The Alchemists Design helps clients create spaces that are both aesthetically pleasing and suited to their everyday needs.

For more information, visit:
https://thealchemistsdesign.com/

GAC Kicks Off 2026 with Strong Overseas Growth, AION V Sets New Sales Record

GUANGZHOU, China, March 24, 2026 /PRNewswire/ — As 2026 begins, GAC takes the lead with an “impressive start” performance: in January this year, its overseas wholesale sales surged 69% year-on-year, continuing the robust growth momentum of the past two years and laying a solid foundation for the 2026 overseas sales target of “300,000 units”. Among them, the AION V set a new monthly retail sales record since its overseas launch.

In terms of regional market highlights, GAC Flourishing Across the Globe: In the Asia-Pacific region, GAC consistently ranks among the top three Chinese brands in sales volume in the Cambodian market; In Europe, retail sales in Greece in January surged 233% month-on-month compared with December, as brand recognition steadily rises with market performance. In the Middle East, the GAC GS8 ranked third among Chinese brands in terms of sales of large SUVs in Kuwait, verifying its product competitiveness in the segment. In the Americas, GAC ranks first sales among Chinese brands in the Dutch Caribbean market of Panama; In Colombia, GAC retains its position among the top three in overall EV sales, with its regional influence continuing to expand.

Behind the strong sales growth lies the continuous launch of high-quality products and solid construction of systematic capabilities. In terms of product layout, the GAC S7 and AION i60, which were launched in China in 2025, are set to make their overseas debut soon, accelerating the product rhythm. These two popular models, highly recognized in the domestic market, are expected to become “growth drivers” for GAC’s overseas product matrix.

In terms of system construction, the “Thousand-Network Plan” continues to advance, with 20 new overseas outlets added in January, bringing the total global network to 650, covering 86 countries and regions across 5 major regions: Asia-Pacific, Middle East and Africa, Europe, CIS and Central and South America, providing sufficient network support for future sales growth. 5 overseas productions have been completed and put into operation, while the AION UT project has reached a key milestone with the successful roll-off of the first prototype from Magna’s factory in Austria. Localization production projects in Cambodia, Brazil and Egypt are also in progress.

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.

GAC’s Advanced Safety Architecture and Next-Generation Powertrain Technologies Earn Worldwide Acclaim

HONG KONG, March 24, 2026 /PRNewswire/ — The global automotive industry is undergoing rapid transformation. At GAC, technological innovation remains at the core of our mission to deliver safer, more efficient, and more reliable mobility experiences for users worldwide. With proprietary core technologies, GAC is accelerating its global footprint and earning trust through quality—trust built on an unwavering commitment to high standards, high requirements, and high quality.


High safety standards are fundamental to our approach. The Magazine Battery represents comprehensive innovation from cell to system. During R&D, GAC subjected the technology to tests far exceeding industry norms and proactively meeting future national standards. Under extreme conditions such as needle penetration, crushing, and twisting, the Magazine Battery does not ignite or explode, mitigating risks at the source. It is this commitment to high standards that transforms technology into a solid foundation of user trust.

GAC applies high requirements throughout the entire vehicle usage cycle. The “GAC X-SOUL Safety Protection System” extends safety across the full lifecycle, enabling early risk identification, intelligent stability control for hazard avoidance—all rigorously validated to standards far exceeding industry benchmarks, from 24/7 monitoring to dual-redundancy backups for key systems. With risks “rehearsed” in advance, round-the-clock protection ensures peace of mind on every journey.

Technological innovation delivers high-quality outcomes. The Quark Electric Drive 2.0, named one of the “World’s Top 10 Electric Drive Systems,” features lightweight construction and high efficiency, delivering powerful performance while reducing energy consumption and enhancing range and responsiveness. The third-generation hybrid technology, also recognized among the “World’s Top 10 Hybrid Systems,” achieves an optimal balance between power and fuel economy through high integration, offering a quiet, smooth, and premium driving experience. These are high-quality breakthroughs in efficiency, performance, and reliability.

From battery safety to intelligent protection, from electric drive efficiency to hybrid driving experience, GAC is redefining the quality benchmark for new energy vehicles with a portfolio of internationally recognized core technologies. As we expand into global markets, GAC will continue to uphold high standards, high requirements, and high quality—bringing China’s innovation power and craftsmanship to more users around the world.

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.

KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF

  • Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase.
  • R&D Expenses was approximately RMB1319.68 million.
  • Loss for the period was RMB381.97 million, adjusted annual loss[1] was approximately RMB211.28 million.
  • Cash and financial assets[2] amounted to approximately RMB4559.36 million, with ample cash reserves.
  • The debt-to-asset ratio[3] further declined to 18.7%.

1. Calculated by deducting equity-settled share-based payment from profit/(loss) for the period.

2. Comprises cash and cash equivalents, restricted deposits, financial assets measured at fair value through profit or loss and financial assets measured at amortized cost.

3. Calculated by dividing the total liabilities by the total assets.

CHENGDU, China, March 24, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company“, Stock Code: 6990.HK) announced its audited consolidated results for the year ended 31 December 2025 (the “Reporting Period“).

Kelun-Biotech is leveraging its core strengths and proprietary OptiDC™ technology platform to continue deepening its presence in the ADC and novel DC drug field. The company is actively advancing cutting-edge modalities including bispecific ADCs, RDCs, iADCs, and DACs, building a differentiated pipeline with strong global competitiveness. At the same time, Kelun-Biotech is steadily advancing product commercialization, achieving transformational growth across its business. To date, the company has four products with eight indications approved for marketing in China, including Sacituzumab Tirumotecan (佳泰莱®), Trastuzumab Botidotin (舒泰莱®), Tagitanlimab (科泰莱®), and Cetuximab N01 (达泰莱®). Among them, three products with five indications have been included in the 2025 National Reimbursement Drug List (NRDL), establishing a fully integrated drug development ecosystem that spans R&D through commercialization.

As of now, the company has built a robust pipeline of more than 30 drug candidates, with over 10 in the clinical stage, and are gradually expanding into broader non-oncology therapeutic areas such as autoimmune diseases and metabolic disorders. Looking ahead, the company will leverage its innovative and differentiated pipeline to deliver high-quality therapeutic solutions for major unmet medical needs worldwide.

Core ADC Products’ Commercialization Realized to Solidify Long-term Performance Foundation 

Sac-TMT (sacituzumab tirumotecan, TROP2 ADC) (also known as SKB264/MK-2870) (佳泰莱®)

TNBC:

  • The Company received marketing authorization in China from the NMPA for sac-TMT in adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting).
  • The Company has initiated a Phase 3 registrational study of sac-TMT monotherapy versus ICC for 1L advanced TNBC.

HR+/HER2- BC:

  • In February 2026, a new indication application for sac-TMT for the treatment of adult patients with HR+/HER2- BC who have received prior endocrine therapy (ET) and at least one line of chemotherapy in advanced setting has been approved for marketing by the NMPA.
  • A Phase 3 registrational study of sac-TMT versus ICC for treatment of patients with HR+/HER2- BC who received prior ET is in progress.

EGFR-mutant NSCLC:

  • In March 2025, the Company received marketing authorization in China from the NMPA for sac-TMT for the treatment of adult patients with EGFR mutant-positive NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. This is the first TROP2 ADC drug approved for marketing in LC globally.
  • In October 2025, the company received marketing authorization in China from the NMPA for sac-TMT for the treatment of adult patients with EGFR mutant-positive NSCLC who progressed after treatment with EGFR-TKI therapy. This is the first ADC globally to show an OS benefit compared with platinum doublet chemotherapy and be approved for advanced NSCLC following progression on only TKI therapy (2L).
  • The Phase 3 registrational study of sac-TMT combined with osimertinib as first-line treatment of EGFR-mutant NSCLC and a Phase 2 study of sac-TMT monotherapy or in combination with osimertinib as neoadjuvant therapy for EGFR-mutant NSCLC are in progress.

EGFR-wild type NSCLC:

  • The Phase 3 registrational study of sac-TMT in combination with KEYTRUDA®[1] (pembrolizumab) versus pembrolizumab as first-line treatment of PD-L1 positive NSCLC met its primary endpoint. This is the first Phase 3 clinical trial of ADC combined with immune checkpoint inhibitor to achieve its primary endpoint in the first-line treatment of NSCLC.
  • In January 2026, sac-TMT in combination with pembrolizumab for the first-line treatment of PD-L1 positive NSCLC were granted Breakthrough Therapy Designation by the NMPA.
  • The Phase 3 registrational study of sac-TMT in combination with pembrolizumab as first-line treatment of PD-L1 negative NSCLC is in progress.

Other indications: The company is actively exploring the potential of sac-TMT both as a monotherapy and in combination with other therapies for treating other solid tumors, including GC, EC, CC, OC, UC, CRPC, HNSCC, and TC, etc.

Trastuzumab botidotin (HER2 ADC, also known as A166, 舒泰莱®)

  • In October 2025, trastuzumab botidotin was approved for marketing by the NMPA for adult patients with HER2+ BC who have received one or more prior anti-HER2 therapy. This is the first domestically developed HER2 ADC approved for 2L+ HER2+ BC in China.
  • An open, multicenter Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ BC that previously received a topoisomerase inhibitor ADC is in progress.

Key Clinical Data Highlighted at International Academic Conferences and in Top Journals

  • Results from the Phase 3 study of sac-TMT for the treatment of 2L EGFR-mutant NSCLC were selected for LBA and presented as an oral report in the Presidential Symposium session at the 2025 ESMO Congress. Sac-TMT achieved statistically significant and clinically meaningful improvements in ORR, PFS, and OS compared to chemotherapy. The study findings were published simultaneously online at the New England Journal of Medicine and in the first issue of 2026.
  • Results from the study of sac-TMT for the treatment of 3L EGFR-mutant NSCLC were presented as an oral report at the ASCO Annual Meeting and published at the British Medical Journal. The final OS analysis of this study will be selected for LBA and presented as a mini oral report at the 2026 ELCC.
  • Results from the Phase 3 study of sac-TMT for the treatment of 2L+ HR+/HER2-BC were selected for LBA and presented as an oral report at the 2025 ESMO Congress.
  • Results from the Phase 3 study of trastuzumab botidotin for the treatment of 2L+ HER2+ BC were selected for LBA and presented as an oral report at the 2025 ESMO Congress.

Sustained Value Release of ADCs Under Development with Tiered Advancement of Innovation Pipeline

Phase 2 clinical stage

SKB315 (CLDN18.2 ADC):

  • The Phase 1b clinical trial of SKB315 is in progress, for the treatment of GC/GEJC/PDAC, etc.
  • Results of a Phase 1 study of SKB315 in patients with advanced solid tumors including GC/GEJC were presented at 2025 ESMO Congress in October 2025.

SKB410/MK-3120 (Nectin-4 ADC):

  • Its partner MSD has launched 4 global Phase 1/2 clinical trial of SKB410/MK-3120 in advanced solid tumor including bladder cancer, etc.

SKB571/MK-2750 (novel bsADC): The Phase 2 clinical trial in China is ongoing.

SKB518 (novel ADC with a potential FIC target): The Phase 2 clinical trials are ongoing in China.

SKB500 (novel ADC): The Phase 2 study is ongoing in China.

Phase 1 clinical stage

SKB107 (RDC)[2]: The Phase 1 study is ongoing.

SKB535/MK-6204 (novel ADC with potential FIC target): The Phase 1 clinical trial for SKB535 is ongoing in China.

SKB445 (novel ADC with potential FIC target): The Phase 1 clinical trials for SKB445 is ongoing in China.

SKB105/CR-003 (ITGB6 ADC): In January 2026, an IND application was approved by the CDE of NMPA for the treatment of advanced solid tumor. A Phase 1/2 trial is ongoing in China.

Strategic Layout of Non-DC Assets with Focus on Combination Therapy & Indication Expansion

Drug candidates for oncology

  • Tagitanlimab (PD-L1 mAb, also known as A167) (科泰莱®): In January 2025, the Company received marketing authorization of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of NPC from NMPA. Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC.
  • In May 2025, the results of a Phase 3 clinical study of tagitanlimab in combination with cisplatin and gemcitabine for the first-line treatment of NPC were presented at the ASCO Annual Meeting.

Cetuximab N01 (EGFR mAb, also known as A140) (达泰莱®):

  • In February 2025, the Company received marketing authorization in China from the NMPA for Cetuximab N01 Injection used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of RAS wild-type mCRC.

Lunbotinib Fumarate Capsules (RET inhibitor, also known as A400/EP0031)(宁泰莱®)[3]

  • An NDA was accepted for review by the CDE of the NMPA of China for the 1L+ treatment of RET-fusion positive NSCLC.
  • The company is also conducting a Phase 1b/2 clinical study for RET+ MTC and solid tumor in China.
  • Ellipses Pharma is progressing their phase 2 clinical study globally outside of China.
  • In May 2025, results from the Phase 1 study of Lunbotinib Fumarate Capsules in patients with advanced RET-mutant MTC were presented at the ASCO Annual Meeting.

SKB118/CR-001 (PD-1/VEGF bsAb):

  • In January 2026, Crescent Biopharma announced the regulatory clearance of the IND application for SKB118 by FDA to initiate its global ASCEND Phase 1/2 clinical trial for the treatment of advanced solid tumors, and the first patient has been dosed in February, 2026.
  • The company is planning to initiate the Phase 1/2 clinical study for SKB118 in China in the first half of 2026.

Drug candidates for autoimmune diseases

SKB378/WIN378 (TSLP mAb):

  • In January 2025, an IND application for SKB378 for the treatment of COPD was approved by the NMPA.
  • Its collaboration partner, Windward Bio, has launched the Phase 2 POLARIS global trial in patients with asthma.

SKB575 (TSLP/undisclosed target bsAb): In March 2026, an IND application for SKB575 for the treatment of atopic dermatitis was approved by the NMPA.

Drug candidates for other non-oncology diseases

SKB336 (FXI/FXIa mAb): The company completed Phase 1 clinical trial in China.

Multiple Products First Included in National Reimbursement Drug List with Accelerated Market Coverage 

In 2025, the Company witnessed an explosive growth in the commercialization of its innovative achievements. The Company has also filed an NDA for Lunbotinib Fumarate Capsules and expects to commence its commercialization in the second half of 2026 or the first half of 2027, subject to regulatory communications and marketing approval. To date, the company’s initial commercial product portfolio, consisting of five products, has taken shape.

Supported by national innovation policies, the Company has successfully secured the first-time inclusion of three of its commercialized products, namely 佳泰莱®, 科泰莱® and 达泰莱®, in the National Reimbursement Drug List (國家醫保藥品目錄), which officially took effect on January 1, 2026, and is expected to benefit more patients faster and better.

Steady Advancement of Global Collaboration and Comprehensive Strength Authoritatively Recognized

Collaboration with MSD: As at the date of this announcement, MSD is evaluating initiated 17 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer, including BC, LC, gynecological cancers, GI cancer and GU cancer. In addition to sac-TMT, the company is also collaborating with MSD on certain ADC assets to continuously explore favorable ADC pipeline portfolios.

Collaboration with Ellipses Pharma: The Company has deepened its collaboration with Ellipses Pharma on A400/EP0031, which has cleared by the FDA to progress into Phase 2 clinical development. As at December 31, 2025, a total of 39 clinical sites in the United States, Europe and UAE were set up for Lunbotinib Fumarate Capsules.

Collaboration with Windward Bio: In January 2025, the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries). Windward Bio has launched the Phase 2 POLARIS global trial in patients with asthma.

Collaboration with Crescent Biopharma. In December 2025, the company and Crescent Biopharma entered into a strategic collaboration for SKB105/CR-003 and SKB118 (a PD1 x VEGF bsAb, also known as CR-001). Under the collaboration, the company granted Crescent Biopharma exclusive rights to research, develop, manufacture and commercialize SKB105/CR-003 in the United States, Europe and all other markets outside of Greater China. In return, the compamy obtained exclusive rights from Crescent Biopharma to research, develop, manufacture and commercialize SKB118/CR-001 in Greater China.

In January 2026, Crescent Biopharma announced the regulatory clearance of the IND application for SKB118 by FDA to initiate its global ASCEND Phase 1/2 clinical trial for the treatment of advanced solid tumors, and the first patient has been dosed in February, 2026.

Continuous Improvement of ESG Capabilities to Consolidate the Foundation for Sustainable Development

Through the establishment and continuous improvement of the ESG governance structure, the Company comprehensively enhances ESG performance ability and ensures the Company’s sustainable development. In May 2025, the company was awarded “Best ESG” by Extel. In March 2026, the Company had received a rating of “AA” in the MSCI ESG Rating Assessment.

Outlook

In 2026, Kelun-Biotech will continue to drive innovation and strengthen its operational capabilities, steadily advancing towards becoming a world-class biopharmaceutical company. Specifically, the Company will implement the following development strategies: advancing differentiated pipelines targeting indications with significant medical needs; innovating on and optimizing payload-linker strategies and novel DC designs and structures, while expanding applications in non-oncology diseases; enhancing its end-to-end drug development and commercialization capabilities; expanding business landscape and strategic partnerships and improve our capabilities for the development, registration and commercialization of our products in ex-China market; and optimizing its operational systems with the aim of becoming a leading global biopharmaceutical company.

About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (referred to as “Kelun-Biotech” Stock Code: 6990.HK) is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., specializing in the R&D, manufacturing, commercialization, and global collaboration of innovative biological drugs and small molecule drugs. The Company focuses on addressing unmet clinical needs both globally and in China, with a strategic emphasis on major disease areas such as oncology, autoimmune disorders, and metabolic diseases. It is dedicated to building an international platform for drug R&D and industrialization, with the aim of becoming a global leader in the innovative drug sector. Currently, Kelun-Biotech has over 30 key innovative drug projects, including 4 projects covering 8 indications that have received market approval, 1 project at the NDA stage, and more than 10 projects in clinical trials. The Company has also successfully established its internationally renowned proprietary ADC and novel conjugated drug platform, OptiDCTM, with 2 ADC projects covering 5 indications approved for market launch, and several ADC or novel conjugated drug projects in clinical or preclinical development.

[1] KEYTRUDA® (Pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

[2] Jointly developed by us and the Affiliated Hospital of Southwest Medical University (西南醫科大學附屬醫院)

[3]  Trade name to be approved by NMPA

 

European Union Pavilion Showcasing Excellence of EU Food and Beverages at FHA 2026

European Excellence Takes Centre Stage at FHA-Food & Hospitality Asia 2026


SINGAPORE – Media OutReach Newswire – 24 March 2026 – The European Union (EU) announces its participation as Region of Honour with dedicated Pavilions at FHA-Food & Hospitality Asia 2026, one of the region’s most important food and beverage exhibitions.

Taking place from 21st to 24th April, visitors will be able to experience the finest of European gastronomy:

At: Singapore Expo
EU Pavilion Locations:

  • FHA Food & Beverage: Hall 5 | Booth 5G4-01
  • ProWine Asia: Hall 10| Booth 10E5-01

Bringing together the best from all 27 EU Member States, the EU Pavilion will present an exceptional range of premium food and beverages, offering an inspiring journey through Europe’s rich culinary heritage.

H.E. Artis Bertulis, European Union Ambassador to Singapore, states “The EU is proud to be the Region of Honour at one of the most prestigious food fairs in Asia to celebrate the excellence and diversity of European food and beverages. Together with country pavilions, the EU is present in full Team Europe spirit highlighting our shared commitment to quality, safe, authentic and sustainable agri-food products.ʺ

PDO PGI Organic Logo 2.jpg

Join us for the opening of the EU Pavilion

Institutional stakeholders, buyers, retailers and distributors are warmly invited to join us for the EU Pavilion’s opening ceremony on 21 April 2026 at 12:00 hrs. The Pavilion will be inaugurated by Ambassador H.E Artis Bertulis and Mr Diego Canga, acting Deputy Director-General at the Directorate-General for Agriculture and Rural Development of the European Commission. The opening ceremony will feature a special live cooking show by the Pavilion’s Star Chef.

You can register for the opening ceremony here.

Registrations close on Monday 20 April. Attendance requires online registration for FHA-Food & Hospitality Asia 2026, which you can do here.

The issuer is solely responsible for the content of this announcement.

About the EU Pavilions

The Pavilions at FHA FnB and ProWine will highlight European agri-food excellence.

Visitors can look forward to tastings of distinctive European products, as well as a vibrant programme of interactive experiences and a wide range of beverages.

Renowned chefs will host live cooking shows, creatively blending European ingredients, including products with and , with traditional local flavours and showcasing their versatility for the Singapore market.

The Pavilions will host expert-led educational sessions delivered by European and Singaporean specialists. These sessions will explore key categories including dairy products, table olives, olive oil and vinegars, meat and meat products, fruit and vegetables, egg products and confectionery. Buyers, retailers and distributors will gain valuable insights into EU standards and discover new opportunities tailored for the Singapore market.